过刊浏览

南蛇藤素在代谢相关脂肪性肝病防治中的研究进展

刘运超^1,2, 张颖², 秦树存^1,3,4, 薛俊莉^1,3,4,*

¹山东第一医科大学第二附属医院中心实验室，泰安 271000；²山东第一医科大学药学院，泰安 271000；³山东省高校重大疾病与氢医学转化应用重点实验室，泰安 271000；⁴山东省卫生健康委员会氢分子生物医学研究重点实验室，泰安 271000

摘要

代谢相关脂肪性肝病(metabolic associated fatty liver disease, MAFLD)是由代谢紊乱引发肝细胞脂肪变性导致的肝脏疾病，与肥胖、糖尿病、代谢功能障碍等因素密切相关。其病理过程由单纯的脂肪变性、肝脏炎症，发展为非酒精性脂肪性肝炎(non-alcoholic steatohepatitis, NASH)，随后导致肝纤维化、肝硬化、肝癌。目前临床上尚无针对MAFLD病因的特效治疗药物。南蛇藤素是中药南蛇藤的主要活性成分，近年来研究发现其在调节脂质代谢、降脂减肥和保肝方面具有广阔的药用价值，具有改善MAFLD的作用。本文综述南蛇藤素在预防和治疗MAFLD方面的相关研究，为南蛇藤素的综合开发利用提供参考依据。

关键词： 南蛇藤素; 脂代谢紊乱; 代谢相关脂肪性肝病

Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease

LIU Yun-Chao^1,2, ZHANG Ying², QIN Shu-Cun^1,3,4, XUE Jun-Li^1,3,4,*

¹Central Laboratory of the Second Affiliated Hospital, Shandong First Medical University, Taian 271000, China；²College of Pharmacy, Shandong First Medical University, Taian 271000, China；³Laboratory of Major Diseases and Hydrogen Medical Translational Applications in Universities of Shandong Province, Taian 271000, China；⁴Key Laboratory of Hydrogen Biomedical Research of Health Commission of Shandong Province, Taian 271000, China

Abstract

Metabolic associated fatty liver disease (MAFLD) is a liver disease with hepatocyte steatosis caused by metabolic disorders, which is closely related to obesity, diabetes, metabolic dysfunction, and other factors. Its pathological process changes from simple steatosis, liver inflammation to non-alcoholic steatohepatitis (NASH), and then leads to liver fibrosis, cirrhosis, and liver cancer. At present, no specific therapeutics are available for treatment of MAFLD targeting its etiology. Celastrol is the main active component of the traditional Chinese medicine Celastrus orbiculatus Thunb. In recent years, it has been found that celastrol shows important medicinal value in regulating lipid metabolism, reducing fat and weight, and protecting liver, and then ameliorates MAFLD. This article reviews the related research progress of celastrol in the prevention and treatment of MAFLD, so as to provide a reference for the comprehensive development and utilization of celastrol.

Key words: celastrol; lipid metabolism disorder; metabolic associated fatty liver disease

收稿日期：　　录用日期：

通讯作者：薛俊莉　　E-mail: xuejunli1988@126.com

DOI: 10.13294/j.aps.2023.0065

引用本文：

刘运超, 张颖, 秦树存, 薛俊莉. 南蛇藤素在代谢相关脂肪性肝病防治中的研究进展[J]. 生理学报 2023; 75 (5): 682-690.

LIU Yun-Chao, ZHANG Ying, QIN Shu-Cun, XUE Jun-Li. Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease. Acta Physiol Sin 2023; 75 (5): 682-690 (in Chinese with English abstract).